Furthermore, rapid and accurate detection of ESR1 alterations based on the advent of newly developed methods for differentiating subtypes and emerging variants resistant to currently used therapies will greatly benefit patients with advanced breast cancers. This evidence concerns the gene ESR1 and breast carcinoma.